ArticleHuman vaccines & immunotherapeutics2019
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Challenges of vaccination information system implementation: A systematic literature review.Human vaccines & immunotherapeutics · 2023Pooled it
- Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.World journal of virology · 2026Review
- Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Epidemiologic and economic impact of introducing a National Immunization Program for herpes zoster vaccination on the prevention of herpes zoster and postherpetic neuralgia in South Korea, an ageing society.Epidemiology and infection · 2026Article
- The association between healthcare access and shingles vaccination among older adults in Virginia, United States.PloS one · 2025Article
- Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50 years in Zhejiang province, China.Frontiers in public health · 2025Article
- Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.Human vaccines & immunotherapeutics · 2023Article
- Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.Human vaccines & immunotherapeutics · 2023Review
- Healthy ageing: Herpes zoster infection and the role of zoster vaccination.NPJ vaccines · 2023Review
- Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States.PharmacoEconomics - open · 2023Article
- Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review.Preventive medicine reports · 2022Review
- Estimated Public Health Impact of the Recombinant Zoster Vaccine.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021Article
- Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.Journal of managed care & specialty pharmacy · 2020Article
- Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.Applied health economics and health policy · 2019Article
- Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccination with RZV in immunocompetent adults aged 50+ years old, including those previously vaccinated with ZVL. The objective of this study was to determine the cost-effectiveness of vaccinating US adults aged 60+ years old, previously vaccinated with ZVL. The ZOster ecoNomic Analysis (ZONA) model, a deterministic Markov model, was adapted to follow a hypothetical 1 million(M)-person cohort of US adults previously vaccinated with ZVL. Model inputs included demographics, epidemiology, vaccine characteristics, utilities and costs. Costs and quality-adjusted life-years (QALYs) were presented over the lifetimes of the cohort from the year of additional vaccination, discounted 3% annually. The model estimated that, vaccination with RZV 5 years after previous vaccination with ZVL, would reduce disease burden compared with no additional vaccination, resulting in a gain of 1,633 QALYs at a total societal cost of $96M (incremental cost-effectiveness ratio: $58,793/QALY saved). Compared with revaccinating with ZVL, vaccination with RZV would result in a gain of 1,187 QALYs and societal cost savings of almost $84M. Sensitivity, scenario, and threshold analyses demonstrated robustness of these findings. Vaccination with RZV is predicted to be cost-effective relative to no additional vaccination, assuming a threshold of $100,000/QALY, and cost-saving relative to ZVL revaccination of US adults aged 60+ years old who have been previously vaccinated with ZVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.